GenFleet Therapeutics
Dong Liu currently serves as the Senior Vice President and Head of Translational Sciences at GenFleet Therapeutics, focusing on the development of target product profiles in oncology and inflammatory diseases. Previously, Liu held the position of Director of Translational Sciences at AstraZeneca, where efforts concentrated on oncology and respiratory therapeutic areas. Prior experience includes a lengthy tenure at Novartis Institutes for BioMedical Research, progressing from Investigator I to Senior Investigator, leading the development of drug candidates in various therapeutic modalities. Liu began a career in research as a Postdoctoral Fellow at the University of California, San Francisco, after earning a Ph.D. in Cellular and Molecular Biology from Columbia University and a B.S. in Molecular Biology from the University of Science and Technology of China.
This person is not in any teams
This person is not in any offices
GenFleet Therapeutics
Dedicated to serving significant unmet medical needs, GenFleet Therapeutics constructs its R&D platform on the basis of disease biology and translational medicine, and researches into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple cutting-edge products with novel mechanisms and global intellectual property rights. Through years of endeavor, GenFleet has set up industry-leading capabilities and expertise in developing novel drugs - both small molecules and biologics. Its cutting-edge pipeline includes over 10 products, three of which have progressed into clinical stages. As more projects move into late-stage clinical trials, GenFleet is expected to unravel its blueprint of commercialization during the next 3-5 years.